GET DAILY SIGNALSAkebia Therapeutics (AKBA) Down -74% – Weighing the Path to the $3.50 Analyst Target
Key Takeaways
- The central $3.50 stock price target is the arithmetic mean of five recent, attributable analyst price targets, reviewed and averaged from individual estimates rather than copied from a single headline consensus.
- At a recent price of about $0.54, reaching $3.50 implies upside of roughly 548%, a very large move by any standard.
- The current target range is wide: $1.00 (Leerink Partners, which downgraded the stock to Market Perform) up to $4.50 (WestPark Capital), reflecting sharply divergent views on the Vafseo launch.
- Supporting factors include a Buy-rated analyst base and Akebia's commercial focus on anemia in chronic kidney disease (CKD), while the biggest risks are a Nasdaq listing deficiency, revenue-recognition setbacks, and repeated target cuts.
- Readers can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages for deeper, continuously updated context.
- For an AI-driven view of shifting market conditions, explore Trending AI Robots, which scan markets for emerging opportunities.
Analyst Price Targets and Consensus View
The $3.50 central target is the arithmetic mean of five recent, individually attributable price targets. BTIG (Julian Harrison) maintained a Buy with a $4.00 target; WestPark Capital (Ed Arce) initiated coverage at $4.50; H.C. Wainwright (Matthew Caufield) reiterated Buy at $4.00; Piper Sandler (Allison Bratzel) held an Overweight rating at $4.00; and Leerink Partners downgraded the stock to Market Perform with a $1.00 target. Averaging these gives $3.50, with an approximate range of $1.00 to $4.50. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Aggregators show somewhat different figures depending on which stale targets they retain. S&P Global data points to a six-analyst average near $3.25, while MarketBeat and TipRanks list means closer to $3.75–$3.90 partly because older, higher targets remain in their systems. The trend is unambiguously downward: H.C. Wainwright and Piper Sandler both trimmed targets from $6 to $4 in February 2026, and Leerink's downgrade in August 2026 reflected concern over the pace of the Vafseo (vadadustat) rollout and a change in a US Renal Care dosing protocol that affected how much revenue could be recognized.
Current Market Position and Path Toward the Target
Akebia Therapeutics closed near $0.54 in early November 2026, down from a 52-week high of $1.89 set a year earlier and not far above its 52-week low of $0.36. The required move to $3.50 is roughly 548%, which is very large by any objective measure. A path toward that level would likely depend on a reacceleration of Vafseo revenue, a restoration of investor confidence in the company's commercial execution, and resolution of its Nasdaq continued-listing status, which Fidelity data flags as deficient. The stock has a market capitalization of only about $148 million and a negative trailing price-to-earnings (P/E) ratio, underscoring how far expectations have reset.
What Could Support a Move Toward the Target
Akebia is a fully integrated biopharmaceutical company with an approved, commercially marketed product: Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) used to treat anemia in adult dialysis-dependent CKD patients. A successful relaunch or sustained prescription growth could lift revenue and sentiment. Analysts who remain constructive have cited "strengthening Vafseo traction" and de-risked clinical data (such as the VOICE trial), while multiple Buy ratings suggest a base of institutional support. A resolution of the listing deficiency or a new strategic partnership could also act as a catalyst.
What Could Prevent the Target From Being Reached
The most immediate obstacle is the Nasdaq continued-listing deficiency, which creates meaningful delisting risk. The stock's steep decline around its November 5, 2026 earnings report reflects disappointment over revenue recognition tied to the US Renal Care dosing protocol, which affected channel inventory and recognized revenue. Analysts have also flagged execution risk around the Vafseo launch. Repeated target reductions, a wide $1.00-to-$4.50 spread, and a negative earnings profile all point to a market that is no longer pricing in a near-term return to the average target.
Technical Levels and Market Structure
From a technical standpoint, Akebia sits well below key prior levels. The $1.00 mark is both the low end of the current analyst range and a psychological threshold, while the area near $1.89 represents the 52-week high and a major resistance zone far above the current price. The recent low near $0.36, set on November 6, 2026, is the nearest meaningful support level below current prices. A sustained move toward $3.50 would require first reclaiming and holding levels above $1.00, a task that implies a multi-fold recovery from today's price.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may apply different assumptions. Investors should watch quarterly Vafseo revenue and prescription trends, any update on the Nasdaq listing deficiency and a possible reverse stock split, changes to analyst targets and ratings, and any news on partnerships or refinancing. Macroeconomic factors such as interest rates and sentiment toward small-cap biotech also matter, since unprofitable development-stage and commercial-stage companies are especially sensitive to funding conditions.
Final Assessment
The $3.50 figure is not a guarantee but a calculated average of five recent analyst targets, spanning a wide $1.00-to-$4.50 range. Reaching it from roughly $0.54 would require a very large recovery of about 548%, and the path is complicated by a Nasdaq listing deficiency, revenue-recognition headwinds, and repeated analyst target cuts. The strongest supports are Vafseo's commercial potential and a still-Buy-leaning analyst base, while the principal obstacles are execution risk, delisting uncertainty, and a small, cash-constrained balance sheet. Investors should treat the target as a reflection of analysts' risk-adjusted expectations rather than a forecast, and monitor Vafseo revenue, listing compliance, and target revisions above all else.
Using Tickeron AI Daily Buy/Sell Signals in My Research
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from evolving market conditions, technical behavior, and AI-driven analysis. For a volatile name like Akebia, where sentiment can shift quickly around earnings and regulatory news, this kind of automated monitoring helps me discover opportunities, keep an eye on existing positions, and spot changing trends more efficiently than manual screening alone. Traders looking for a systematic, data-driven way to stay on top of shifting conditions may find the signals a useful complement to their own research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
AKBA's RSI Oscillator recovers from oversold territory
The RSI Indicator for AKBA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 30 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +35.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 223 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In 64 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for AKBA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.445) is normal, around the industry mean (6.379). P/E Ratio (-3.344) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs for the treatment of anemia and vascular diseases
Industry PharmaceuticalsGeneric
Advertisement